Consumers who want to understand OpenLoop's data practices can review the telehealth consent form published at openloophealth.com/telehealth-consent
Three-Month Progress: Sustained Weight Loss With Compounded Semaglutide By week 12, most patients using semaglutide injections have lost between 8 and 15 percent of their starting body weight, depending on adherence and lifestyle factors
It was approved in 2019 for diabetes management
Additional benefits observed: Substantial reduction in knee osteoarthritis pain (75.8% reduction in pain scores) Improved cardiovascular risk markers (non-HDL cholesterol, triglycerides, blood pressure) Up to 86% of participants with fatty liver disease achieved normal liver fat levels Early research suggests retatrutide may lead to substantial weight loss in clinical trial settings, but long-term safety, tolerability, and real-world outcomes still need more data
This results in improved insulin sensitivity and a significant reduction in blood glucose levels
Requires consultation with a healthcare provider if theres a history of thyroid cancer, pancreatitis, or kidney disease